Form 8-K - Current report:
SEC Accession No. 0001493152-26-021112
Filing Date
2026-05-04
Accepted
2026-05-04 16:10:33
Documents
13
Period of Report
2026-05-01
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 42026
2 EX-3.1 ex3-1.htm EX-3.1 10112
  Complete submission text file 0001493152-26-021112.txt   264944

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ernaw-20260501.xsd EX-101.SCH 3749
4 XBRL DEFINITION FILE ernaw-20260501_def.xml EX-101.DEF 26590
5 XBRL LABEL FILE ernaw-20260501_lab.xml EX-101.LAB 36622
6 XBRL PRESENTATION FILE ernaw-20260501_pre.xml EX-101.PRE 25214
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5277
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 26937671
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)